Cargando…
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s disease
Recent genome-wide association studies have revealed genetic risk factors for Alzheimer’s disease (AD) that are exclusively expressed in microglia within the brain. A proteomics approach identified moesin (MSN), a FERM (four-point-one ezrin radixin moesin) domain protein, and the receptor CD44 as hu...
Autores principales: | Du, Yuhong, Bradshaw, William J., Leisner, Tina M., Annor-Gyamfi, Joel K., Qian, Kun, Bashore, Frances M., Sikdar, Arunima, Nwogbo, Felix O., Ivanov, Andrey A., Frye, Stephen V., Gileadi, Opher, Brennan, Paul E., Levey, Allan I., Axtman, Alison D., Pearce, Kenneth H., Fu, Haian, Katis, Vittorio L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245921/ https://www.ncbi.nlm.nih.gov/pubmed/37292860 http://dx.doi.org/10.1101/2023.05.22.541727 |
Ejemplares similares
-
Discovery of FERM domain protein–protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer’s disease
por: Du, Yuhong, et al.
Publicado: (2023) -
Fused Tetrahydroquinolines
Are Interfering with Your
Assay
por: Bashore, Frances M., et al.
Publicado: (2023) -
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
por: Bashore, Frances M., et al.
Publicado: (2023) -
Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023) -
The identification of FERM domain protein in serum infected with Plasmodium berghei
por: P.G., Vathsala, et al.
Publicado: (2016)